Tags |
|
|
Links |
|
|
Top Articles - How You Can Still Beat the Institutional Money to One of the Best Plays in the Stock Market for 2007
If you look at the price for Newmont mining (NEM) as of February, it illustrates that large institutional money is still not on board with gold
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
yet and in addition, for this reason, Newmont would be a solid anchor for your gold portfolio. How do I know from looking at this chart that ins
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
titutional money is not on board yet? Because NEM is the most well known major gold stock (actually it may be the only one though I’m not sure)
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
hat is a component of the U.S. S&P 500 index. As such, this is the one stock that all institutional managers are familiar with and the one they
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
will dump loads of money into once they finally get on board with gold.
Gold has risen about $60-$70 an ounce since the beginning of the year,
Gold has risen about $60-$70 an ounce since the beginning of the year,
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
r roughly 10%, yet the price of Newmont has only risen from $44.20 a share at the begging of the year to $45.81 as of early February, or just a
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
measly 3.6%, amazingly underperforming the price of gold itself! Why is this amazing? Because the strongest, best gold stocks typically will out
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
perform the actual appreciation in the price of physical gold by multiples of 2, 3, 5, and even higher. This statistic tells me, as Newmont is t
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
e most prominent gold stock of the lot in the eyes of institutional fund managers (note not in my eyes, but in the eyes of institutional manager
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
s) that they are not on board yet at all.
So why would I say that if you haven’t already bought Newmont, that it’s not too late to buy Newmont
So why would I say that if you haven’t already bought Newmont, that it’s not too late to buy Newmont
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ow? Because when the rest of the thundering sheep herd out there finally climbs on board, so will all the institutional managers, and since the
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
overwhelming number of institutional managers in the United States have no idea how to evaluate gold stocks to choose the best ones, they will u
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
ndoubtedly just dump money into the “safe” gold stock - which I believe will be Newmont, or possibly Barrick Gold, if I had to pick one stock.
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
n addition, it’s always a good idea to have some “anchors” in your gold portfolio. Newmont can certainly fulfill that role as one of your anchor
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
s.
Although I’m sure that Canadian institutional managers are much more knowledgeable about selecting gold stocks since a great deal of “resour
Although I’m sure that Canadian institutional managers are much more knowledgeable about selecting gold stocks since a great deal of “resour
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
e” stocks trade on the Toronto and Vancouver exchanges, still given the relative size of the U.S. stock market in comparison to the Canadian mar
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ket, U.S. fund managers that eventually start investing in gold stocks will influence the price of gold stocks with their purchases, and Newmont
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
is the stock most likely to benefit from their realization, even if it comes late in the game.
By far, Newmont won’t be the gold stock that wi
By far, Newmont won’t be the gold stock that wi
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
l appreciate the most or grant investors legendary profits. In order to achieve this, you simply must take the time to learn how to identify gre
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
at gold stocks. It’s not about following the media and the institutional buyers that will make you wealthy. It’s about beating them to the punch
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/102185/toparticles-How-You-Can-Still-Beat-the-Institutional-Money-to-One-of-the-Best-Plays-in-the-Stock-Market-for-2007.html">How You Can Still Beat the Institutional Money to One of the Best Plays in the Stock Market for 2007</a>
BB link (for phorums):
[url=http://www.toparticles.org.ua/article/102185/toparticles-How-You-Can-Still-Beat-the-Institutional-Money-to-One-of-the-Best-Plays-in-the-Stock-Market-for-2007.html]How You Can Still Beat the Institutional Money to One of the Best Plays in the Stock Market for 2007[/url]
Related Articles:
Drop Shipping-Can It Work for Your Small Business?
Affiliate Business: There's Nothing Quite Like It
Bookmark it:
|